MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.41
+0.12
+0.90%
Opening 14:44 11/22 EST
OPEN
13.33
PREV CLOSE
13.29
HIGH
13.50
LOW
13.15
VOLUME
18.98K
TURNOVER
--
52 WEEK HIGH
22.66
52 WEEK LOW
9.50
MARKET CAP
569.20M
P/E (TTM)
-6.4480
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLLS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLLS News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.1d ago
  • Cellectis gene editing patent upheld in Europe
  • seekingalpha.1d ago
  • Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
  • Business Wire.1d ago

More

Industry

Biotechnology & Medical Research
+1.62%
Pharmaceuticals & Medical Research
+0.73%

Hot Stocks

Name
Price
%Change

About CLLS

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
More

Webull offers Cellectis SA (ADR) (CLLS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.